Early Dual Antiplatelet Therapy — Competitive Intelligence Brief

Early Dual Antiplatelet Therapy (Early Dual Antiplatelet Therapy) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet therapy (DAPT). Area: Cardiovascular.

phase 3 Dual antiplatelet therapy (DAPT) Cyclooxygenase (COX) and P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Early Dual Antiplatelet Therapy (Early Dual Antiplatelet Therapy) — Beijing Tiantan Hospital. Early dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Early Dual Antiplatelet Therapy TARGET	Early Dual Antiplatelet Therapy	Beijing Tiantan Hospital	phase 3	Dual antiplatelet therapy (DAPT)	Cyclooxygenase (COX) and P2Y12 receptor
clopidogrel + aspirin OR prasugrel + aspirin	clopidogrel + aspirin OR prasugrel + aspirin	Abbott Medical Devices	marketed	Dual antiplatelet therapy (DAPT)	P2Y12 receptor (clopidogrel/prasugrel) and cyclooxygenase (aspirin)
Standard-DAPT of Ticagrelor plus aspirin	Standard-DAPT of Ticagrelor plus aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor	P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet therapy (DAPT) class)

1. Abbott Medical Devices · 1 drug in this class
2. Beijing Tiantan Hospital · 1 drug in this class